Unknown

Dataset Information

0

Stopping Oral Polio Vaccine (OPV) After Defeating Poliomyelitis in Low- and Middle-Income Countries: Harmful Unintended Consequences? Review of the Nonspecific Effects of OPV


ABSTRACT: Abstract

Background

The live vaccines bacille Calmette-Guérin (BCG) and measles vaccine have beneficial nonspecific effects (NSEs) reducing mortality, more than can be explained by prevention of tuberculosis or measles infection. Live oral polio vaccine (OPV) will be stopped after polio eradication; we therefore reviewed the potential NSEs of OPV.

Methods

OPV has been provided in 3 contexts: (1) coadministration of OPV and diphtheria-tetanus-pertussis (DTP) vaccine at 6, 10, and 14 weeks of age; (2) at birth (OPV0) with BCG; and (3) in OPV campaigns (C-OPVs) initiated to eradicate polio infection. We searched PubMed and Embase for studies of OPV with mortality as an outcome. We used meta-analysis to obtain the combined relative risk (RR) of mortality associated with different uses of OPV.

Results

First, in natural experiments when DTP was missing, OPV-only compared with DTP + OPV was associated with 3-fold lower mortality in community studies (RR, 0.33 [95% confidence interval {CI}, .14–.75]) and a hospital study (RR, 0.29 [95% CI, .11–.77]). Conversely, when OPV was missing, DTP-only was associated with 3-fold higher mortality than DTP + OPV (RR, 3.23 [95% CI, 1.27–8.21]). Second, in a randomized controlled trial, BCG + OPV0 vs BCG + no OPV0 was associated with 32% (95% CI, 0–55%) lower infant mortality. Beneficial NSEs were stronger with early use of OPV0. Third, in 5 population-based studies from Guinea-Bissau and Bangladesh, the mortality rate was 24% (95% CI, 17%–31%) lower after C-OPVs than before C-OPVs.

Conclusions

There have been few clinical polio cases reported in this century, and no confounding factors or bias would explain all these patterns. The only consistent interpretation is that OPV has beneficial NSEs, reducing nonpolio child mortality. Oral polio vaccine is associated with beneficial nonspecific effects in relation to its current use as a birth dose, as 3 infant doses coadministered with diphtheria-tetanus-pertussis vaccine, and as a campaign vaccine delivered to all children <5 years of age.

SUBMITTER: Aaby P 

PROVIDER: S-EPMC9348612 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6953375 | biostudies-literature
| S-EPMC9897637 | biostudies-literature
| S-EPMC4766913 | biostudies-other
| S-EPMC5853416 | biostudies-literature
| S-EPMC6206102 | biostudies-literature
| S-EPMC9975221 | biostudies-literature
| S-EPMC3547540 | biostudies-literature
| S-EPMC3280341 | biostudies-literature
| S-EPMC8166165 | biostudies-literature
| S-EPMC7457624 | biostudies-literature